Literature DB >> 12037220

Peripheral airway obstruction in primary pulmonary hypertension.

F J Meyer1, R Ewert, M M Hoeper, H Olschewski, J Behr, J Winkler, H Wilkens, C Breuer, W Kübler, M M Borst.   

Abstract

BACKGROUND: As there is controversy about changes in lung function in primary pulmonary hypertension (PPH), lung mechanics were assessed with a focus on expiratory airflow in relation to pulmonary haemodynamics.
METHODS: A cross sectional study was performed in 64 controls and 171 patients with PPH (117 women) of mean (SD) age 45 (13) years, pulmonary artery pressure (PAPmean) 57 (15) mm Hg, and pulmonary vascular resistance 1371 (644) dyne.s/cm(5).
RESULTS: Mean (SD) total lung capacity was similar in patients with PPH and controls (98 (12)% predicted v 102 (17)% predicted, mean difference -4 (95% confidence interval (CI) -7.89 to -0.11); residual volume (RV) was increased (118 (24)% predicted v 109 (27)% predicted, mean difference 9 (95% CI 1.86 to 16.14); and vital capacity (VC) was decreased (91 (16)% predicted v 102 (10)% predicted, mean difference -11 (95% CI 15.19 to -6.80). RV/TLC was increased (117 (27)% predicted v 97 (29)% predicted, mean difference 20 (95% CI 12.3 to 27.8)) and correlated with PAPmean (r=0.31, p<0.001). In patients with PAPmean above the median of 56 mm Hg, RV/TLC was further increased (125 (32)% predicted v 111 (22)% predicted, mean difference -14 (95% CI -22.2 to -5.8)). Expiratory flow-volume curves were reduced and curvilinear in patients with PPH.
CONCLUSIONS: Peripheral airway obstruction is common in PPH and is more pronounced in severe disease. This may contribute to symptoms. Reversibility of bronchodilation and relation to exercise capacity need further evaluation.

Entities:  

Mesh:

Year:  2002        PMID: 12037220      PMCID: PMC1746348          DOI: 10.1136/thorax.57.6.473

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  26 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  RESPIRATORY AND CARDIOVASCULAR FUNCTION IN PATIENTS WITH SEVERE PULMONARY HYPERTENSION.

Authors:  H U WESSEL; P KEZDI; D W CUGELL
Journal:  Circulation       Date:  1964-06       Impact factor: 29.690

3.  Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group.

Authors:  H Olschewski; H A Ghofrani; T Schmehl; J Winkler; H Wilkens; M M Höper; J Behr; F X Kleber; W Seeger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

4.  Cardiopulmonary function in patients with pulmonary hypertension.

Authors:  N Gazetopoulos; N Salonikides; H Davies
Journal:  Br Heart J       Date:  1974-01

5.  Pulmonary function studies as an aid in the differential diagnosis of pulmonary hypertension.

Authors:  M H Williams; J J Adler; C Colp
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

6.  Determinants of maximal expiratory flow from the lungs.

Authors:  N B Pride; S Permutt; R L Riley; B Bromberger-Barnea
Journal:  J Appl Physiol       Date:  1967-11       Impact factor: 3.531

7.  [Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension]].

Authors:  R Ewert; C Opitz; R Wensel; J Winkler; G Höffken; W Frank; F Berger; F X Kleber; R Hetzer
Journal:  Z Kardiol       Date:  2000-11

8.  Inefficient ventilation and reduced respiratory muscle capacity in congestive heart failure.

Authors:  F J Meyer; C Zugck; M Haass; L Otterspoor; R H Strasser; W Kübler; M M Borst
Journal:  Basic Res Cardiol       Date:  2000-08       Impact factor: 17.165

9.  Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance.

Authors:  F J Meyer; M M Borst; C Zugck; A Kirschke; D Schellberg; W Kübler; M Haass
Journal:  Circulation       Date:  2001-05-01       Impact factor: 29.690

Review 10.  Role of endothelin-1 in lung disease.

Authors:  K A Fagan; I F McMurtry; D M Rodman
Journal:  Respir Res       Date:  2001-02-22
View more
  26 in total

Review 1.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  [Diagnosis and therapy of chronic pulmonary hypertension].

Authors:  Horst Olschewski; M M Hoeper; M M Borst; R Ewert; E Grünig; F-X Kleber; B Kopp; C Opitz; F Reichenberger; A Schmeisser; D Schranz; I Schulze-Neick; H Wilkens; J Winkler; H Worth
Journal:  Clin Res Cardiol       Date:  2007-05       Impact factor: 5.460

3.  Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension.

Authors:  Gulsev Ozen; Chabha Benyahia; Salma Mani; Kamel Boukais; Adam M Silverstein; Richard Bayles; Andrew C Nelsen; Yves Castier; Claire Danel; Hervé Mal; Lucie H Clapp; Dan Longrois; Xavier Norel
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

4.  [Heart or lung? : Diagnostics and management of unclear exertional dyspnea].

Authors:  H Wilkens; M Held
Journal:  Herz       Date:  2018-09       Impact factor: 1.443

Review 5.  Pulmonary Limitations in Heart Failure.

Authors:  Ivan Cundrle; Lyle J Olson; Bruce D Johnson
Journal:  Clin Chest Med       Date:  2019-06       Impact factor: 2.878

6.  Effect of cardiac resynchronization therapy on pulmonary function in patients with heart failure.

Authors:  Ivan Cundrle; Bruce D Johnson; Virend K Somers; Christopher G Scott; Robert F Rea; Lyle J Olson
Journal:  Am J Cardiol       Date:  2013-06-05       Impact factor: 2.778

7.  Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma.

Authors:  Anand C Patel; Mark L Van Natta; James Tonascia; Robert A Wise; Robert C Strunk
Journal:  J Allergy Clin Immunol       Date:  2008-10       Impact factor: 10.793

8.  Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.

Authors:  Mariana Faria-Urbina; Keith T Ung; Laurie Lawler; Lawrence S Zisman; Aaron B Waxman
Journal:  Pulm Circ       Date:  2021-05-13       Impact factor: 3.017

9.  Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.

Authors:  Annette S Droste; David Rohde; Mirko Voelkers; Arthur Filusch; Thomas Bruckner; Mathias M Borst; Hugo A Katus; F Joachim Meyer
Journal:  Respir Res       Date:  2009-12-30

10.  Imitators of exercise-induced bronchoconstriction.

Authors:  Pnina Weiss; Kenneth W Rundell
Journal:  Allergy Asthma Clin Immunol       Date:  2009-11-17       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.